 price
result prime pathway de-risk
admittedli lower expect easi comp
impact new product push organ growth hsd
number often associ organ dental
growth howev real standout quarter
margin saw y-o-i step bp look
forward ds world one primescan trade-in
program help off-set tougher comp
improv result well
continu cost program caus us
rais out-year estim rais price target
howev remain rate valuat
compani trade near histor high
absolut rel basi thu see risk/reward
continu confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
gm effici initi price fx
venlo disrupt
one ds launch septemb
earli execut encourag result
demand creation approach custom one
om effici initi price
lt think grow
number innov product launch categori
like endo restor
work hard manufactur enough unit meet demand
upgrad program start octob us
prior cerec owner owner compet
believ accret result
half om improv higher sale growth includ
primescan destock
rest effici initi
cfo improv oper effici cash convers
mm cost save end
major impact eur
lot drop gm
improv rigor get approv
result lower quarter time tick
return long-term run-rat
still quarter two away understand run-rat impact
primescan approv major geographi ex-china
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk includ slowdown global dental market failur restructur busi hit manag long-term
articl articl
time dissemin novemb
analyst elizabeth anderson suzi yoon primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
